Each year, respiratory syncytial virus quietly claims the lives of roughly 100,000 children under five — most of them in places where a hospital is a distant hope rather than a nearby certainty. The World Health Organization has now prequalified a multi-dose vial formulation of the maternal RSV vaccine Abrysvo, a logistical refinement that could mean the difference between a medicine that exists and one that actually reaches the people who need it. By immunizing pregnant women in their third trimester, protective antibodies cross the placenta and guard newborns through their most fragile first
WHO Prequalifies Multi-Dose Maternal RSV Vaccine to Expand Global Infant Protection
RSV causes approximately 100,000 deaths annually among children under 5 years old, with nearly half occurring in infants younger than 6 months, predominantly in low- and middle-income countries.
Many infants die at home, never reaching clinical care.
Mark
So the WHO just approved a different version of a vaccine that was already approved. Why does that matter enough to announce?
Mimi
Because the version they approved before was in single-dose vials. This one comes in multi-dose vials. That sounds small, but for countries with limited budgets and cold storage, it changes whether a vaccination program is actually feasible.
Luke
Feasible in theory, though. Do we know if any countries have actually committed to rolling this out, or is this just regulatory clearance?
Mimi
The prequalification is the regulatory step. Gavi already approved funding for maternal RSV programs in July, so there is money available. But you're right—approval and actual deployment are different things.
Mark
What is the actual disease burden we are talking about here? Why does RSV matter so much?
Mimi
A hundred thousand children die from it every year, mostly under five. Nearly half of those are babies under six months old. And 97 percent of the deaths happen in low- and middle-income countries where people cannot get to a hospital.
Luke
That hundred thousand figure—is that WHO's best estimate, or is there uncertainty around it?
Mimi
It is WHO data, so it is their best estimate based on available surveillance. But you are right to flag it: in countries with weak reporting systems, the true number could be higher or lower. We do not have perfect visibility.
Mark
How does the vaccine actually work?
Mimi
A pregnant woman gets vaccinated in her third trimester. Her body makes antibodies against RSV. Those antibodies cross the placenta to the baby, protecting the infant during the first six months when RSV is most dangerous.
Luke
And we know that works? There is clinical evidence?
Mimi
Yes. The single-dose version was already approved based on clinical trials. This is the same vaccine, just packaged differently.
Mark
So what is the actual barrier now? If the vaccine works and it is approved and there is funding, what stops countries from using it?
Mimi
Implementation. Training health workers. Integrating it into antenatal clinics. Making sure pregnant women actually show up. The vaccine is ready. The systems to deliver it are not always there yet.
Der Puls
- RSV kills approximately 100,000 children under five every year, with nearly half those deaths striking infants younger than six months — and 97% occurring in low- and middle-income countries where clinical care is often out of reach.
- Single-dose vial formats, higher per-shot costs, and cold-chain demands had quietly kept an already-approved maternal vaccine from scaling in the health systems that need it most.
- The WHO's prequalification of a multi-dose vial version of RSVpreF (Abrysvo) directly targets those logistical chokepoints — fewer vials to manage, lower costs per dose, and simpler distribution for overstretched clinics.
- The Gates Foundation helped fund the multi-dose formulation, signaling that the barrier to reach was recognized as an engineering and economics problem, not just a scientific one.
- National governments and antenatal care programs must now move to integrate maternal RSV vaccination into existing systems — the vaccine and its affordable format are ready, but political will and infrastructure remain the open questions.
Each year, respiratory syncytial virus quietly claims the lives of roughly 100,000 children under five — most of them in places where a hospital is a distant hope rather than a nearby certainty. The World Health Organization has now prequalified a multi-dose vial formulation of the maternal RSV vaccine Abrysvo, a logistical refinement that could mean the difference between a medicine that exists and one that actually reaches the people who need it. By immunizing pregnant women in their third trimester, protective antibodies cross the placenta and guard newborns through their most fragile first months of life. The science was already there; what this moment addresses is the harder, older problem of how to make a good thing possible at scale.
The World Health Organization has prequalified a multi-dose vial version of the maternal RSV vaccine RSVpreF (Abrysvo), a packaging change that carries outsized consequences for the world's most vulnerable infants. The vaccine itself was not new — the WHO had approved its single-dose form in March 2025, with Gavi endorsing it that July. What changed this week was the format, and in global health, format can be everything.
Respiratory syncytial virus hospitalizes more than 3.6 million children under five each year and kills around 100,000 of them. Nearly half of those deaths occur in infants younger than six months. The geography of the crisis is unsparing: 97 percent of RSV child deaths happen in low- and middle-income countries, where families frequently cannot reach care in time and infants die at home.
The vaccine works through a biological handoff — a pregnant woman vaccinated from week 28 onward generates antibodies that cross the placenta, giving her newborn a protective shield through its first six months of life. The Gates Foundation helped fund the multi-dose formulation, recognizing that cost and logistics, not science, were the true barriers to scale.
For health systems already stretched thin, the multi-dose vial reshapes what is operationally possible. Fewer discarded vials, simpler storage, lower per-dose costs, and more predictable clinic planning all compound into something meaningful: a maternal immunization campaign that a health ministry can actually budget for and a nurse can actually run. Prequalification does not resolve every obstacle — training, political commitment, and access still matter — but it removes one that had quietly stood between a proven vaccine and the mothers it was designed to protect.
The formulation is ready. The affordability is improved. What follows depends on whether governments and health programs move quickly enough to weave maternal RSV vaccination into the antenatal care that pregnant women are already seeking.
The World Health Organization has cleared a new formulation of a maternal respiratory syncytial virus vaccine for use across lower-income countries, betting that a simpler packaging choice will reach more infants before the virus does.
The vaccine in question, RSVpreF (Abrysvo), already existed in single-dose form when the WHO approved it in March 2025. Gavi, the Vaccine Alliance, followed with its own endorsement that July. But the real shift came this week: the WHO prequalified a multi-dose vial version of the same vaccine. The change is practical rather than scientific. A single vial containing multiple doses costs less per shot and requires less cold-chain infrastructure to distribute—two things that matter enormously when you are trying to vaccinate pregnant women in countries where healthcare systems are already stretched thin.
The numbers that drive this decision are stark. Respiratory syncytial virus hospitalizes more than 3.6 million children under five each year globally and kills roughly 100,000 of them. Nearly half those deaths occur in infants younger than six months, the window when maternal vaccination offers the most protection. What makes the geography of this crisis particularly brutal is that 97 percent of RSV deaths in children happen in low- and middle-income nations, where families often cannot reach a hospital in time. Many infants die at home, never reaching clinical care.
The vaccine works by a simple biological handoff. A pregnant woman receives the shot during her third trimester, typically from week 28 onward. Her immune system generates antibodies against RSV. Those antibodies cross the placenta and enter the fetus, providing a shield during the infant's first six months of life—the period of greatest vulnerability. The Gates Foundation helped fund and develop this multi-dose formulation, recognizing that cost and logistics were the real barriers to scale.
For health systems in resource-limited settings, the multi-dose vial changes the calculus of what is possible. A single vial means fewer needles, less waste, simpler storage, and a lower per-dose price tag. It means a nurse can plan a maternal immunization clinic without worrying that she will have to discard half-used single-dose vials. It means a country's health ministry can actually budget for a campaign that reaches meaningful numbers of pregnant women. The prequalification does not solve every problem—access, training, and political will still matter—but it removes one significant obstacle that had stood between a vaccine and the mothers who need it.
What happens next depends on how quickly national governments and health programs can integrate maternal RSV vaccination into their existing antenatal care systems. The vaccine exists. The formulation that makes it affordable exists. The question now is whether the infrastructure and commitment will follow.
Bemerkenswerte Zitate
The multi-dose format is designed to enhance the ability of national healthcare systems to plan, finance, and execute large-scale immunization campaigns.— WHO prequalification rationale
Möchten Sie die ganze Geschichte?
Das Original lesen bei respiratory-therapy.com ↗
Health & Medicine